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Efficacy and tolerance of -2b interferon therapy on HCV infection of
hemodialyzed patients. A high frequency (25%) of anti-hepatitis C virus(HCV) antibodies is observed in French hemodialyzed patients; this is
associated with detectable viremia in 85% and results in chronic hepatitis
in more than 90%. We conducted a pilot study to examine the tolerance
and efficacy of n-2b Interferon therapy upon HCV infection in hemodia-
lyzed patients. Nineteen anti-HCV positive hemodialyzed patients were
given a standard a-2b interferon regimen (3 megaunits subcutaneously
three times weekly, following each hemodialysis) over six months as a
treatment of biopsy-proven chronic hepatitis (N = 16) or acute hepatitis(N = 3). Thirteen of these 19 had increased levels of aminotransferase at
the time of treatment. Serum HCV RNA was tested qualitatively and
quantitatively by the polymerase chain reaction and the bDNA test,
respectively, at the beginning and at the end of antiviral treatment, and a
third time at least six months after the end of therapy (mean follow-up 18
9 months). HCV genotype was determined in the 15 patients who had
detectable HCV RNA before treatment. The biological response (long-
term response, relapse or non-response) was defined as usual according to
the serum aminotransferase levels during therapy and at least six months
after. A post-treatment liver biopsy, allowing comparison with semiquan-
titative pathological scores, was performed in 14 patients. Only one of the
19 treated patients did not complete therapy because of poor tolerance,
while 18 of the 19 fairly tolerated a complete six month course of a-2b
interferon. Among the 13 patients who had increased activities of amino-
transferase prior to therapy, a long-term response, a relapse or a non-
response was observed in 8, 3 and 2 patients, respectively. Genotype lb
was the most prevalent (8 of 15). Although HCV RNA was still detectable
in only 46.7% by PCR and 36.4% by bDNA at the end of antiviral therapy,
despite biological and histopathological improvement in most, in all but
three patients serum HCV RNA reappeared during follow-up. Biological
and histopathological improvement was also noted in those patients who
had hepatitis despite undetectable HCV RNA before antiviral treatment.
a-2b Interferon therapy of HCV hepatitis in hemodialyzed patients is well
tolerated and is as efficient as in the general population. The frequency of
virological relapse after discontinuation suggests that reinforced therapeu-
tic schedules should be proposed to hemodialyzed patients. Discrepancies
between biological, virological and histopathological results underline the
need of an exhaustive post-treatment evaluation, including liver biopsy.
As kidney transplant recipients, hemodialyzed patients often
are multiply transfused before the introduction of the recombi-
nant erythropoietin therapy [1], and thus, they are frequently
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infected by hepatotropic viruses. The systematic vaccination
against the hepatitis B virus in hemodialyzed patients and in those
with renal failure [2, 31, as well as improved hygiene and isolation,
have led to a dramatic decline of the HBs antigen chronic carriage
[4]. By contrast, over the same period, iterative blood transfusion
supply before the validation in blood donors of the surrogate
markers of non-A, non-B infection [5] and of antibodies against
the hepatitis C virus (anti-HCV) [6] resulted in an epidemicity of
HCV infection in the dialysis setting [7—9]. Indeed, the prevalence
of anti-HCV antibodies is increased worldwide in hemodialyzed
as compared to the general population [10—13]. As an example,
anti-HCV were found in 25% of French hemodialysis patients [12]
as compared to 0.3 to 0.7% in blood donors [14]. This high
frequency of anti-HCV is mainly related to the number of blood
units and to the duration of dialysis [12, 13]. Recently we
described in hemodialysis patients that, firstly, anti-HCV antibod-
ies were associated in 85% of the cases with detectable HCV
RNA indicating an on-going viral replication and, secondly, HCV
viremia led to chronic hepatitis in 95% of patients [15]. Most
patients had normal biological liver tests despite active infection
and chronic liver disease, including cirrhosis as previously de-
scribed in hemodialysis patients [16] and kidney recipients [4] with
HBV-related chronic liver disease. Furthermore, viremic patients
could be the source of nosocomial transmission which accounts
for 5 to 20% of HCV infection in the dialysis and transplantation
setting [11, 15—17].
These points raise the question of antiviral treatments in
hemodialyzed patients, especially in those who are candidates for
kidney transplantation. Indeed, renal transplantation is usually
associated with a worsening of liver lesions in patients with HBV-
or non-A, non-B-related liver disease [18]. Renal transplantation
is a contra-indication to cs-interferon therapy, which is the sole
efficient treatment of HCV infection, because an increased risk of
graft rejection and a poor efficacy [19, 20]. Alpha-interferon has
now been widely used in the treatment of HCV infection in the
general population [21, 22]. With a standard treatment of 3
megaunits thrice weekly, subcutaneously for six months, 50% of
patients undergo a response, as assessed by the normalization of
aminotransferase activities. However, 50% of them will relapse
after interferon withdrawal, resulting in 25% of so-called long-
term response which may be, although not constantly, associated
with disappearance of HCV RNA from serum, liver or PBMC
[23—25].
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The aim of the present prospective pilot study was to evaluate
the tolerance and the efficiency of a standard s-interferon treat-
ment of hepatitis C infection in hemodialyzed patients as assessed
upon biological, virological and pathological analysis.
Methods
Inclusion criteria were chronic dialysis and the presence of
anti-HCV antibodies associated with biopsy-proven chronic hep-
atitis or acute hepatitis.
Patients
Nineteen anti-HCV positive patients were included in the
present pilot study. There were 14 men and 5 women, with a mean
age of 45 years and a mean dialysis duration of 94 65 months.
Sixteen patients had previously received blood products and were
considered to be transfusionally infected patients (mean delay 38
50 months); all these patients underwent a liver biopsy which
showed chronic hepatitis, of which two were with cirrhosis. Twelve
patients underwent a post-treatment liver biopsy. Three of the 19
patients had an acute HCV infection in the absence of blood
transfusion suggesting a riosocomial contamination; they had no
liver biopsy before treatment, but two underwent a post-treatment
liver biopsy.
One patient had mixed cryoglobulinemia associated with HCV
infection. None had membranoproliferative glomerulonephritis
which could be attributed to an HCV infection leading to an
immune complex disease.
Increased levels of serum aminotransferase activities were
present in 13 of the 19 patients (68.4%) before the antiviral
treatment, a figure which is normal in hemodialyzed as well as in
kidney recipients with viral chronic hepatitis [4, 15, 16].
Virology
Serological anti-HCV assays. Serum antibodies to HCV were
detected with the second generation HCV enzyme-linked immu-
nosorbent assay (ELISA2) or recombinant immunoblot assay
(RIBA2) from Ortho Diagnostic, according to the manufacturer's
instructions.
Extraction of RNA and cDNA synthesis. Viral RNA was ex-
tracted from 100 1.il of serum using a modification of the gua-
nidium isothiocyanate method of Chomezynsky and Sacchi [26]
(RNAzol B, Bioprobe Systems) and resuspended after isopropa-
nol precipitation in 30 l of H20 DEPC with 40 units of RNAsin
(GIBCO-BRL). Ten microliters of RNA solution were incubated
at 65°C for 10 minutes with 10 pmol of downstream primer. eDNA
was synthesized at 37°C for 45 minutes with 100 units of MMLV
reverse transcriptase (Bethesda Research Laboratories, Gaithers-
burg, MD, USA) in a 30 jil reaction mixture containing 50 mM
Tris-HC1 pH 7.5,75 mM KC1, 6 mM MgC12, and 1 mMNTP. eDNA
was stored at —20°C.
PCR and genotyping procedure. We performed a single tube
nested PCR, to amplify the 5' untranslated region (UTR). This is
a modified version of nested PCR where both amplification steps
are realized without reopening the tube, to reduce the risk of
contamination by PCR product carryover to a minimum [27]. One
fifth of the eDNA was amplified in 50 d of PCR mix (dNTP: 125
jsM each, 50 mM KCI, 1.5 mivi MgC12, 0.01% gelatine), containing
5 pmol of each outer primer (SR1-5'-TGCACGGTCTAC-
GAGACCTC-3', SF1 -5' -GCCATGGGGYrAGTATGAGT-3')
and 1.5 units of cloned Taq polymerase (Perkin Elmer Cetus,
Norwalk, CT, USA). This first mix was then covered with 200 d
of high density oil (dimethylpolysiloxane AK 350; Walker-Chemie
GmbH, MUnchen, Germany). The second PCR mix (150 d, with
80 pmol of each inner primer SR2 (5'-GGGCAOI'CGCAAGCAC-
CCTAT-3', SF2-(5 '-GTGCAGCCTCCAGGACCCCC-3' and no
Taq polymerase) was injected onto the surface of oil, forming a
droplet within it. At the end of the first amplification the tubes
were centrifuged for one minute (to mix the second PCR mixture
with the first) and the second amplification was thus carried out.
The sensitivity of the method was maintained despite our modi-
fications. We also rigourously undertook all precautions to pre-
vent false positive results [28]. The PCR method used in this study
is qualitative, giving positive or negative results for HCV RNA
detection.
Genotype-specific probes-based assay. A nested PCR assay using
universal primers in the 5'UTR was carried out using sets of
biotinylated primers in which sequence degeneracy was included
to allow annealing to all HCV genotypes [29]. PCR was per-
formed in one-tube nested PCR as described previously. PCR
products were subjected to electrophoresis on a 2% agarose gel,
stained with ethidium bromide and observed under ultraviolet
light. The samples visible on agarose gel were genotyped with the
HCV 1iPA procedure (vide infra).
LiPA procedure. One tenth of biotinylated PCR fragments was
hybridized to oligonucleotides directed against the variable re-
gions of the 5' UTR, immobilized as parallel lines on membrane
strips (Line Probe Assay, LiPA; Innogenetics, Belgium). After
hybridization, streptavidin labeled with alkaline phosphatase was
added, and incubation with NBT/BCIP chromogen allowed the
development of the colorimetric reaction. Hybridization condi-
tions and colour development were as described by Stuyver et a!
[29]. The reactivity of the amplified fragments with one or more
lines on the strip allows the recognition of the genotype of HCV.
The five major genotypes (1 to 5) and their subtypes (Ia, ib, 2a,
2b, 3a, 3b, 4 and 5a) were identified, according to the nomencla-
ture of Simmonds et al [30].
Branched DNA assay (bDNA): Quantitation of HCV RNA. Fifty
microliters of serum sample was tested for HCV RNA with the
b-DNA test (Quantiplex-HCV RNA Chiron Corp.) using the
manufacturer's protocol. This sandwich assay with signal amplifi-
cation is based on specific hybridization of synthetic oligonucleo-
tides (capture and labeling extenders) to the 5' untranslated and
core regions of HCV RNA in a crude serum lysate. The bDNA
assay is quantitative and gives results in numbers of copies of
HCV genome equivalents per milliliter (Eq/ml). The sensitivity
threshold of b-DNA test for HCV RNA detection is about 3.5 iO
Eq/mI.
A 50 il serum sample was lysed, and HCV RNA was hybridized
to capture probes coated onto microwell surface. Synthetic bDNA
amplifier molecules and multiple copies of an alkaline phos-
phatase-linked probe were hybridized to the immobilized com-
plex. Detection was achieved by incubating the complex with a
chemiluminescent substrate (dioxetane) measuring the light emis-
sion. The signal is proportional to the level of target nucleic acid.
Biology
Serum aspartate aminotransferase and alanine aminotransfer-
ase activities were measured in every case by using the serum from
the same blood sample as that used for the serological assays.
Enzyme activities were assayed using a fast centrifugal analyzer
Fig. 1. Examples in hemodialyzed patients of a
long-term response (patient •), a nonresponse
(patient •) or a relapse (patient •) to a-
interferon therapy. Long term response,
nonresponse and relapse are defined according
to the course of alanine aminotransferase
(ALAT, upper normal value <45 lU/liter)
(solid line) and of the branched DNA assay
which allows quantitation of HCV RNA
(sensitivity of the bDNA: 350,000 genomes EqI
ml) (dotted line).
(Cobas Bio Roche). Hypertransaminasemia was arbitrarily de-
fined as an increase of aminotransferase levels over the upper
limit of normal.
Urinanalysis (sediment and proteinuria) in those patients with
urine output has not been systematically performed and thus will
not be included in the results.
Histopathological analysis
Liver biopsy samples were embedded in paraffin. Sections were
stained with hematoxylin and eosin and Pens stain. Chronic liver
disease was classified as chronic hepatitis or cirrhosis. For an
accurate evaluation of the activity of the liver disease, a semiquan-
titative scoring system was blindly used on the pre- and post-
treatment liver biopsy according to the Knodell's classification
[311. This classification scores periportal necrosis (range from 0 to
10), intralobular necrosis (0 to 6), inflammation (0 to 4) and
fibrosis (0 to 4) and allows comparison of activity (necrosis plus
inflammation) and fibrosis in a given patient who experienced
serial liver biopsies.
Treatment schedule
Patients received a standard a-2b recombinant interferon
(IFNa) treatment [21, 22]: 3 megaunits IntronA® subcutaneously
three times weekly (and 500 mg paracetamol intravenously) after
each hemodialysis for six months. Blood samples were withdrawn
monthly for follow-up of aminotransferase activities and blood
counts. HCV RNA was tested by PCR and the b-DNA test before
and following the antiviral treatment and at the last follow-up
control. The biological response to antiviral therapy was defined
as usual. Responders were those patients who normalized
transaminase activities within the three first months of treatment:
long-term responders still had normal transaminase activities
during therapy and at least six months after therapy, while
transaminase activities increased in the relapsers after cessation of
treatment. Nonresponders were defined as those patients who did
not normalize transaminase activities during therapy. Thus, the
biological response could be evaluated in the 13 patients who had
persistently increased aminotransferase levels before treatment.
Results
Only one of the 19 treated patients withdrew from interferon-a
treatment after two months because of poor clinical (marked
fatigue) and biological (anemia and marked increase of gamma-
glutamyl transpeptidase) tolerance, and inefficiency as assessed by
a stable increase in aminotransferases activities. Eighteen of the
19 (94.7%) received a complete six-month course of IFNa with a
fair tolerance, despite a frequent flu-like syndrome.
Aminotransferase activities during therapy
A biological response to therapy was evaluable in the 13
patients who had increased activities of aminotransferases prior to
therapy (Fig. 1). A response, as defined by normalization of
aminotransferase activities, was observed in 11 (84.6%). Among
these 11 responders, a mean follow-up of 18 9 months (6 to 32)
led to define eight long-term responders (72.7%) and three
relapsers (27.3%) with, respectively, either normal or increased
value of aminotransferase at least six months after discontinuation
of interferon-a (Table 1). Six patients had still normal activities of
aminotransferase during the entire study, before and after treat-
ment, and could therefore not be evaluated only on the basis of
this test.
Virological analysis
Main results are summarized in Table 1. The virological
analysis was based on the PCR and bDNA procedures. The
polymerase chain reaction identified repeatedly detectable HCV
RNA in the serum of 15 of 19 (78.9%) patients prior to IFNa
therapy. At the end of therapy, HCV RNA was still detectable in
the serum of seven (46.7%) of these 15 patients who had
detectable HCV RNA before treatment. Thus, interferon-a ap-
peared efficient in stopping HCV replication in one half of the
patients. At the end of follow-up, HCV RNA was undetectable by
PCR in three (20.0%) of the 15 patients who had detectable HCV
RNA before treatment. Among the 11 so-called responder pa-
tients as defined by the biological liver tests, HCV was detectable
in eight and three before and after treatment, and in six patients
at the end of follow-up.
1414 Pol et al: Interferon therapy of HCV infection and dialysis
30
LU 20
.c
125
105
8565
-J
'+0
25
5
MO M2 M4 M6 M8 M10 M12
Interleron a-2b, 3MU 3/week
Pol et al: Interferon therapy of HCV infection and dialysis 1415
Table 1. Virological response according to the bDNA and the PCR
assay in 19 hemodialyzed patients who received standard IFN-a
treatment
Biological response
patient no.
bDNA/PCR
HCV
genotype
Before
IFN-a
After
IFN-a
At the
end of
follow-up
Long-term responders
1 42/+ 11.91+ 11.31+ 1 a
2 0/— 0/— 0/— nonevaluable
3 01+ 0/— 0/— la+lb
4 0/— 0/— 0/— unevaluable
5 01+ 01+ 0/+ 3a
6 0/— 0/— 0/— nonevaluable
7 14.61+ 0/— 0/— 5 a
8 24.6/83+ 0/— 10.11+ 2 a
Relapsers9 6.41+ 0/— 5.81+ 1 b
10 0/+ 0/— 41.4/+ 1 b
11 34.9/+ 81.3/+ 118/+ 1 b
Nonresponders
12 33/+ 0/+ 28/+ 1 b
13 43.4/+ 16/+ 138/+ 1 b
Indeterminate
14 4.8/+ 0/— 12.8/+ 1 b
15 0/— 0/— 0/— nonevaluable
16 0/+ 0/— 0/— 1 b
17 33.51+ 0/— 4.2/+ 2 a
18 22.2/+ 33.8/+ 23.6/+ 1 b
19 3.6/+ 0/+ 121/+ 4 a
The bDNA assay detected HCV RNA before treatment in the
serum of 11 of 19 (57.9%) patients. At the end of therapy, HCV
RNA was still detectable in the serum of four of these 11 patients
(36,4%) and of 10 patients at the end of the follow-up. Among the
11 so-called responders as defined by the biological liver tests,
HCV RNA was detectable by the bDNA assay in five and two
before and after treatment, and in five at the end of follow-up. In
those patients who had detectable viremia, the titers of HCV
RNA before and after treatment were not clearly different.
Amplification products allowed the determination of the HCV
genotype in 15 of 19 patients. Genotype lb was identified in eight,
genotype 2a in two, genotype la, 3a, 4a and 5a in one for each. An
additional patient had a mixed infection, due to both la and lb
genotypes.
Histopathological analysis
Among the 19 patients, fourteen underwent a post-treatment
liver biopsy. In six of the eight long-term responders as defined by
biological criteria, one still had mild chronic hepatitis although in
the other five patients, necrosis and inflammation disappeared
despite the persistence of serum HCV RNA in all but two patients
(Table 2). In a non-responder, the liver histology became normal
despite detectable HCV viremia. In patients with constantly
normal transaminase activities despite chronic hepatitis, three
cleared the histological signs of activity (1 had a normal liver
despite ongoing HCV infection and 1 still had nodular regenera-
tive hyperplasia) although two patients had no improvement in
liver histology, including one patient with histological deteriora-
tion.
Table 2. Histopathological analysis of the liver of 19 hemodialyzed
patients who received standard IFN-a treatment
Biological
response,
patient no.
Liver histology/Knodell score
Before IFN-a After IFN-a
Long term
responders
1 Chronic hepatitis/1-0-1-i ND
2 Lobular hepatitis/1-3-1-1 Chronic hepatitis/1-0-i-3
3 Chronic hepatitis/1-1-1-0 Normal liver/0-0-1-0
4 ND (acute hepatitis) Normal liver/0-O-0-0
5 Chronic hepatitis/1-0-1-i ND
6 Chronic hepatitis/1-0-3-i Normal liver/0-0-0-0
7 Chronic hepatitis/3-0-3-i Mild lesions/0-0-1-1
8 Active cirrhosis/3-0-3-4 Active cirrhosis/1-0-3-4
Relapsers
9 ND (acute hepatitis) ND
10 Chronic hepatitis/1-0-3-1 Chronic hepatitis/1-0-3-1
11 ND (acute hepatitis) Chronic hepatitis/0-0-3-1
Nonresponders
12 Chronic hepatitis/0-0-3-0 Normal liver/0-O-0-1
13 Chronic hepatitis/3-0-3-1 ND
Indeterminate
14 Chronic hepatitis/1-1-3-1 Chronic hepatitis/1-1-3-i
15 Active cirrhosis/1-1-3-4 Inactive cirrhosis/0-0-0-4
16 Chronic active hepatitis/
1-1-1-1 + NRH
NRH/0-0-0-1
17 Chronic hepatitis/1-1-i-0 Chronic hepatitis/1-1-3-1
18 Chronic hepatitis/1-1-3-i ND
19 Chronic hepatitis/i-i-i-i Normal liver/0-0-0-0
Abbreviations are: ND, not done; NRH, nodular regenerative hyper-
Discussion
plasia.
This prospective pilot study establishes that standard a-inter-
feron therapy (3 megaunits thrice weekly subcutaneously for 6
months) given to hemodialyzed patients has a fair tolerance and
an efficacy which is not different from that of the general
population. Indeed, only one of the 19 patients had to withdraw
from treatment because of poor tolerance. Furthermore, standard
a-interferon treatment in the general population leads to a
biological response in 50% of patients, of whom 50% will relapse
after withdrawal of treatment, leading to the biological definition
of long-term response in around 25% of patients, of relapse in
25% and of non-response in 50% [21, 221. In the present study,
a-interferon induced a biological response in 11 of 13 patients, a
long-term response in eight of the 13 hemodialyzed patients and
also suppressed HCV viremia in a half of hemodialyzed patients,
figures which are quite similar to what is reported for the general
population. These encouraging data could result from an en-
hanced efficacy of interferon, in relation with the renal failure
which may increase its half-life. Indeed, it has been recently
suggested, although debated, that increased dosages of a-inter-
feron may improve the response rate [24]. Several clinicopatho-
logical studies have emphasized that good response to interferon
therapy was associated with the absence of cirrhosis [32], young
age and recent infection [331. It is noteworthy that our patients
predominantly shared these characteristics since only two had
cirrhosis, and three an acute HCV infection. This low frequency of
cirrhosis in our series, as compared to 20% in the general
population with HCV infection, may reflect either the short
duration of infection (38 50 months) or a more benign course
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of HCV chronic hepatitis in hemodialyzed patients. The primary
renal disease did not appear as a factor of response to interferon.
In addition, virological parameters, HCV genotypes and quan-
titative viremia, have been described as having important impli-
cations [23, 34, 35]. The genetic variability of the HCV genome
has already led to the definition of at least 12 genotypes, nomen-
clature of which has been recently clarified [30]. There is a mixing
of different HCV types within a given area, although some
genotypes may have a preferential geographical distribution [36,
371• Infections by genotype lb are associated with severe liver
disease (cirrhosis and hepatocellular carcinoma) which could
reflect different intrinsic properties (a more cytopathic effect of
the genotype lb is suggested in liver transplant recipients) [38] or
differences in the chronological epidemiology of HCV genotypes
[39]. Moreover, infections by genotype lb are associated with a
lower rate of response to interferon therapy than infections by
genotypes la, 2a or 3a [33, 35, 40]. In the present study, only eight
of the 15 patients (53.3%) in whom efficient amplification proce-
dure allowed the genotype determination, had an infection by
genotype ib, a figure lower than the 67.2% that we have previ-
ously reported for the general population [34]. Quantitation of
HCV viremia also has clinical implications. Indeed, although it is
still debated whether levels of viremia vary according to the
histological status [23] or the genotype [34], several reports
describe concordant results dealing with quantitative HCV vire-
mia and interferon efficiency: a high level of HCV viremia is an
independent factor for low response to interferon [34]. In the
present study viremia was usually low and four of the 19 patients
had no detectable HCV viremia (see below). These virological
parameters may, as well as the clinicopathological patterns of our
patients, partially explain the encouraging results.
An important issue is that most of hemodialyzed responders
relapsed after the discontinuation of the antiviral treatment, since
HCV RNA was undetectable at the end of follow-up in only three
of the 15 patients who had pre-treatment detectable viremia.
These results are similar to those recently reported for interferon
cs-2a therapy of mixed cryoglobulinemia associated with hepatitis
C virus infection. Fifteen of 25 (60%) patients had a virological,
clinical and biochemical response but all these patients relapsed
after interferon a-2a was discontinued [411. This is not strikingly
different from results obtained in the general population [23—25].
Indeed, randomized controlled trials have shown that interfer-
on-a therapy was effective in inducing long-term remission in
around 20% of patients with chronic hepatitis. In most studies,
long-term response, as defined by normal aminotransferase activ-
ities persisting after withdrawal of interferon, was clearly associ-
ated in at least 60% of patients with disappearance of HCV RNA
from serum, liver or PBMC which indicates eradication of the
virus [25]. Some lines of evidence indicate that higher dosages of
a-interferon may slightly increase the primary rate of response
and that a prolonged duration of treatment (12 to 18 months)
could markedly reduce the relapse rate after a-interferon discon-
tinuation [24, 421. Moreover, therapeutic combination with a new
nucleoside analog, Ribavirin, appears to improve the response
rate in naive patients or in non-responders to interferon alone [43,
44]. Our results suggest that other therapeutic schedules, includ-
ing higher doses of interferon-a, a longer treatment period and
the use of additional antiviral drugs, should be evaluated to
improve eradication of HCV infection in hemodialyzed patients.
It is noteworthy that most responders, as well as one non-
responder and two patients who were not biologically evaluable,
markedly improved their liver status despite reappearance or
persistance of detectable HCV viremia. Such patients could
benefit from treatment by becoming "symptomless carriers" of
HCV. Symptomless carriage of HCV (detectable HCV viremia
with normal aminotransferase levels and histologically normal
liver) appears spontaneously after HCV contamination [45] or
after an antiviral treatment [23, 24], as observed in our study.
Further work should elucidate the significance of symptomless
carriage and thus the clinical implications of discrepancies be-
tween biological, virological and histological results which have
been recently reported in patients who received alpha interferon
[46, 471.
Finally, histological improvement did not appear to correlate
with the biological response and there was no clear relationship
between the height of the aminotransferase level and the response
to therapy.
Another important point is that HCV RNA was not detectable
in four of our 19 patients despite biopsy-proven chronic hepatitis
or acute hepatitis. This may correspond to a methodological
problem of sensitivity. Undetectable HCV RNA by both PCR and
bDNA procedures might reflect a very low HCV viremia despite
the presence of HCV RNA in the liver or PBMC (which has not
been assayed). Alternatively, one might hypothesize non-A,
non-B, non-C infection [48]. Interestingly, most of these non-
viremic patients biologically and histologically benefit from the
antiviral treatment.
In summary, a-interferon therapy of HCV hepatitis in hemo-
dialyzed patients is well tolerated and its efficacy is not strikingly
different from that observed in the general population. The
frequency of virological relapse after discontinuation of a-inter-
feron suggests that "reinforced" therapeutic schedules should be
proposed to hemodialyzed patients. Discrepancies between the
biological, virological and histopathological results of antiviral
treatment underline the need of liver biopsies in the follow-up of
treated patients, which may improve their biological and his-
topathological liver status despite relapse of HCV viremia or
despite the absence of detectable HCV viremia before treatment.
Addendum
We have now treated (or are treating) nine additional hemo-
dialyzed patients for HCV infection with 3 megaunits of a-2b
interferon thrice weekly after each dialysis for six months. Bio-
logically, seven of the nine had normal aminotransferase levels
before treatment. The two patients with hypertransaminasemia
normalized aminotransferase levels within the first two months of
treatment. One of these nine patients had to withdraw a-2b
interferon therapy because poor clinical tolerance with diffuse
myoclonia, which spontaneously regressed. We have, however, no
sufficient follow-up yet in these patients to evaluate virological
and histological efficacy.
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